Engineered Mesenchymal Stem Cells for Targeting Solid Tumors: Therapeutic Potential beyond Regenerative Therapy

Shen Cheng, Susheel Kumar Nethi, Sneha Rathi, Buddhadev Layek, and Swayam Prabha

Departments of Experimental and Clinical Pharmacology (S.C., S.K.N., B.L., S.P.) and Pharmaceutics (S.R., S.P.), College of Pharmacy, University of Minnesota, Twin Cities, Minnesota

Received May 6, 2019; accepted June 5, 2019

ABSTRACT

Mesenchymal stem cells (MSCs) have previously demonstrated considerable promise in regenerative medicine based on their ability to proliferate and differentiate into cells of different lineages. More recently, there has been a significant interest in using MSCs as cellular vehicles for targeted cancer therapy by exploiting their tumor homing properties. Initial studies focused on using genetically modified MSCs for targeted delivery of various proapoptotic, antiangiogenic, and therapeutic proteins to a wide variety of tumors. However, their use as drug delivery vehicles has been limited by poor drug load capacity. This review discusses various strategies for the nongenetic modification of MSCs that allows their use in

tumor-targeted delivery of small molecule chemotherapeutic agents.

SIGNIFICANCE STATEMENT

There has been considerable interest in exploiting the tumor homing potential of MSCs to develop them as a vehicle for the targeted delivery of cytotoxic agents to tumor tissue. The inherent tumor-tropic and drug-resistant properties make MSCs ideal carriers for toxic payload. While significant progress has been made in the area of the genetic modification of MSCs, studies focused on identification of molecular mechanisms that contribute to the tumor tropism along with optimization of the engineering conditions can further improve their effectiveness as drug delivery vehicles.

Introduction

Mesenchymal stem cells (MSCs) are adult, multipotent progenitor cells known for their self-renewal ability, and have shown considerable potential in regenerative medicine. More recently, their use in anticancer therapies has gained considerable interest owing to their tumor homing capabilities. Targeted delivery of chemotherapeutics for the treatment of cancer is a goal that has not yet been fully realized due to various physiologic and pathologic obstacles. Development of cell-based active targeting approaches using macrophages (Choi et al., 2007, 2012; Cheng et al., 2010), red blood cells (Chambers and Mitragotri, 2007), neural stem cells (Cheng et al., 2013; Schnarr et al., 2013), MSCs (Roger et al., 2010), and T cells (Huang et al., 2015) has created a new avenue for targeting cancer therapies to malignant tissues. Of these cell-based strategies, MSCs (Nakamizo et al., 2005; Müller et al., 2006; Tang et al., 2010; Ahmed and Lesniak 2011; Sadhukha et al., 2014) and macrophages (Batrakova et al., 2007; Bryniskikh et al., 2010; Zhao et al., 2011) are particularly interesting owing to their potential to efficiently infiltrate specific tumor types (Touboul et al., 2013). MSCs have been genetically engineered using viral and nonviral vectors to secrete cytokines

that improve host immune response against cancer cells as well as other proteins that can directly mediate tumor cell death (Hodgkinson et al., 2010). For example, MSCs have been genetically modified to express interleukin (IL)-2 (Nakamura et al., 2004), IL-12 (Ryu et al., 2011), IL-18 (Xu et al., 2009), CXCR4 (Yang et al., 2013), prodrug-activating enzymes against tumors (Amara et al., 2014), tumor necrosis factor-related apoptosis-inducing ligand (Mueller et al., 2011), and interferon- β (Ling et al., 2010). In addition, MSCs have been engineered to carry traditional anticancer cytotoxic drugs (Sadhukha et al., 2014). Many of these newer efforts have focused on using nano delivery systems to incorporate small molecules in MSCs. This review will discuss the progress that has been made in the development of MSCs as tumor-targeted therapeutics, with emphasis on nongenetic modification of MSCs to deliver small molecule chemotherapeutics.

MSCs: Origin, Sources, and Traditional Uses

MSCs were first discovered by A.J. Friedenstein in the early 1970s (Afanasyev et al., 2009), and since then have been successfully isolated from numerous tissues including bone marrow (Stewart et al., 1999; Chamberlain et al., 2007), adipose (Wagner et al., 2005; Zhang et al., 2011; Pendleton et al., 2013), peripheral blood (Ab Kadir et al., 2012), skin (Bartsch et al., 2005; Riekstina et al., 2008), brain (Kang et al., 2010), dental tissues (Gronthos et al., 2002), and endometrium

This work was supported by funding received from the Minnesota Ovarian Cancer Alliance, Betty and Terry Noble Gift for Ovarian Cancer Research, and National Institutes of Health [Grant No. R01EB022558] (to S.P.).
<https://doi.org/10.1124/jpet.119.259796>

ABBREVIATIONS: DBCO, dibenzyl cyclooctyne; IL, interleukin; LDGI, lipids, doxorubicin, gold nanorods, and iron oxide nanoclusters; MSC, mesenchymal stem cell; NP, nanoparticle; PLGA, poly(L-lactide-co-glycolide).

(Cheng et al., 2017). They are characterized by the presence of several surface markers such as CD105, CD73, and CD90 and the absence of certain markers such as CD45, CD34, and CD14 or CD11b, CD19, and HLA-DR (Baghaei et al., 2017).

MSCs are multipotent and can primarily differentiate into adipocytes (Dennis et al., 1999; van Vliet et al., 2007), osteoblasts (Friedenstein et al., 1966; Bruder et al., 1997, 1998), and chondrocytes (Solchaga et al., 2011). However, the differentiation potential of MSCs is not just limited to mesodermal lineages (Kadiyala et al., 1997), and can differentiate into epithelial cells, hepatocytes (endodermal), and neural (ectodermal) cell lineages when provided appropriate signals. This ability to differentiate into various cell types has resulted in their extensive use in regenerative medicine and tissue engineering (Park et al., 2015; Fitzsimmons et al., 2018). In fact, the utilization of MSCs has been considered one of the most exciting advances in stem cell transplantation (Garcia-Castro et al., 2008). There are currently over 700 clinical trials investigating the use of MSCs as clinical therapeutics (Wang et al., 2018a). MSCs have been investigated for direct repair of various tissues such as bone (Lin et al., 2017), heart (Thakker and Yang, 2014), kidney (Morigi et al., 2016), and skin (Laverdet et al., 2014). MSCs have shown positive results in studies involving hematopoietic transplantation (Zhao and Liu, 2016), arthritis therapy (Ansboro et al., 2017), intervertebral disk repair (Noriega et al., 2017), and many others. In addition to growth and differentiation, other characteristics of MSCs such as migration (De Becker and Riet, 2016), stable long-term transduction (Liu et al., 2018), and lack of immunogenicity (Morandi et al., 2008) suggest that these cells can be used for therapeutic uses beyond regenerative medicine.

MSCs for Tumor-Targeted Delivery

Obstacles to successful treatment of malignant tumors include the development of tumor drug resistance and the insufficient tumor selectivity of anticancer drugs leading to acute and long-term host morbidities (Housman et al., 2014). Encapsulation in nano delivery systems can enable passive targeting of the drug to the tumor tissue and addresses these obstacles to some extent. However, passive

targeting is inefficient and does not result in uniform distribution of the drug within the tumor tissues. Active targeting approaches use ligands capable of binding surface antigens or receptors that are overexpressed on tumor cells (Bazak et al., 2015). However, active targeting is, in reality, not an active process since the delivery system must first accumulate passively in the tumor, followed by binding to tumor cells (Rosenblum et al., 2018). Thus, active or ligand-based targeting suffers from some of the same limitations as passive targeting. MSCs have been shown to actively traffic to both primary tumors and metastases (Layek et al., 2016) in response to inflammatory signals secreted by neutrophils and macrophages infiltrating the tumor (Sun et al., 2014). MSCs have been genetically modified to express peptides and proteins with antitumor properties. For example, significant anticancer effects against tumors of brain, ovary, pancreas, liver, kidney, breast, or prostate and pulmonary metastases were observed with MSCs genetically engineered to express suicidal genes (thymidine kinase, cytosine deaminase, and carboxylesterase) (Kucerova et al., 2008; Song et al., 2011; Yin et al., 2011). Thus, it is possible to achieve true active tumor targeting with MSCs. In fact, several anticancer therapies utilizing MSCs are in various stages of clinical development (Table 1). In addition, recent studies show that MSCs infiltrate tumor tissue uniformly and thus improve the intratumoral distribution of the therapeutic agents they carry (Bexell et al., 2012).

Tumor homing potential of MSCs is attributed to the presence of surface-associated chemokine receptors such as CXCR4 and their interaction with chemokines secreted on the surface of tumor cells (Gao et al., 2007). Although the mechanism of tumor tropism of MSCs is not fully understood, transendothelial migration of MSCs toward tumors is considered to be similar to that of leukocytes, which involves steps such as rolling, adhesion, and extravasation (Fig. 1). In addition, MSCs express various adhesion molecules such as intercellular adhesion molecules (e.g., intercellular adhesion molecule-1 and intercellular adhesion molecule-2) and vascular cell adhesion molecule-1, which also contribute to their intrinsic migratory properties (Hernanda et al., 2014). Tumors are enriched with various chemokines such as stromal

TABLE 1

Ongoing/completed clinical studies using MSCs as cancer therapeutics (<https://clinicaltrials.gov/>; <http://www.clinicaltrialsregister.eu/>)

Delivery System	Administration Route	Sponsor	Indication	Development Phase	Status	NCT Number
MSCs secreting IFN- β	Intraperitoneal	M.D. Anderson Cancer Center, Dallas TX	Ovarian cancer	Phase 1	Active, not recruiting	NCT02530047
MV-NIS infected adipose tissue-derived MSCs	Intraperitoneal	Mayo Clinic, Rochester MN	Recurrent ovarian cancer	Phase 1/2	Recruiting	NCT02068794
Bone marrow-derived autologous MSCs infected with ICVIR5, an oncolytic adenovirus (CELYVIR)	Intravenous	Hospital Infantil Universitario Niño Jesús, Madrid, Spain	Metastatic and refractory solid tumors	Phase 1/2	Completed	NCT01844661
MSCs genetically modified to express TRAIL	Intravenous	University College, London	Lung adenocarcinoma	Phase 1/2	Recruiting	NCT03298763
Autologous human MSCs genetically modified to express HSV-TK, which catalyzes the phosphorylation of the prodrug ganciclovir to the toxic compound ganciclovir triphosphate	Intravenous	Apceh GmbH & Co. KG, Germany	Advanced gastrointestinal cancer	Phase 1/2	Completed	2012-003741-15 (EudraCT number)

EudraCT, European Union Drug Regulating Authorities Clinical Trials; HSV-TK, herpes simplex virus thymidine kinase; IFN- β , interferon- β ; MV-NIS, oncolytic measles virus encoding thyroidal sodium iodide symporter; NCT, National Clinical Trials; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.

Fig. 1. The physical parameters and cell surface molecules of MSCs cooperate to induce active homing of MSCs to tumors. Endothelial cells are green; MSCs are blue; and tumor cells are pink. Although the mechanisms of MSC homing are poorly understood, they likely involve partially overlapping steps of deceleration in the blood flow (which may be partially physical; here, depicted as bulging endothelial cells), rolling, adhesion, transmigration through the endothelium, and migration into surrounding tissues. The possible molecular determinants are indicated. The elucidation of the MSC homing mechanism to tumors will facilitate the development of drugs for inhibition of this process (endogenous MSCs) and contribute to the understanding of how ex vivo cultured MSCs can be engineered to be used as effective and specific drug delivery vehicles. Reproduced from Droujine et al. (2013).

cell-derived factor-1 α , vascular endothelial growth factor A (Ball et al., 2007), basic fibroblast growth factor (Schmidt et al., 2006), and transforming growth factor β (Ponte et al., 2007), which act as chemoattractants for MSCs.

Characteristics Enabling the Use of MSCs as Targeted Carriers

As discussed previously, several characteristics of MSCs such as ability to self-renew, ease of isolation, and tumor tropism make them ideally suited for tumor targeting. In addition, MSCs have demonstrated low immunogenicity in vivo (Lee et al., 2014). They have been found suitable for allogeneic use due to lack of major histocompatibility complex class II molecules and relatively low levels of major histocompatibility complex class I molecules (Squillaro et al., 2016). MSCs are easily expanded in vitro due to their natural adherence to tissue culture flasks. Furthermore, MSCs have limited replicative lifespan (Kim and Park, 2017), ensuring low risk of malignant transformations following transplantation in vivo. Also, the use of MSCs is devoid of ethical considerations unlike in the case of embryonic stem cells (Mahla, 2016).

Engineered MSCs for Tumor-Targeted Drug Delivery

Engineered cell-based systems have emerged as excellent platforms for addressing various challenges faced by synthetic delivery systems including site-specific delivery. Cells can be engineered to present natural biomolecules or synthetic ligands to overcome various physiologic barriers and control their interaction with the tumor microenvironment.

Genetic Modification of MSCs. Over the past few decades, genetically engineered MSCs have been successfully used to express therapeutic peptides and proteins for the treatment of both localized and metastatic tumors. For instance, MSCs expressing IL-12 showed potent anticancer activity against melanoma, breast cancer, and hepatoma (Chen et al., 2008).

Similarly, MSCs expressing interferon- γ were shown to inhibit tumor growth in mouse neuroblastoma (Relation et al., 2018) and lung carcinoma (Yang et al., 2014) models. Genetic modification of MSCs is usually performed using viral and nonviral vectors. Transient gene expression and low-transfection efficiency are the limitations observed in genetic modification of MSCs using the nonviral vectors (Park et al., 2015). Moreover, viral transduction methods for genetic engineering of MSCs pose high risk of chromosomal instability (Takeuchi et al., 2007), insertional mutagenesis (Bokhoven et al., 2009), and proto-oncogene activation (Modlich et al., 2009) despite inherent high transfection efficiency.

Nongenetic Modification of MSCs. The successes achieved with genetically modified MSCs suggest that MSCs can also serve as potential carriers for tumor-specific delivery of small molecule therapeutics including cytotoxic agents. Pessina et al. (2011) initially demonstrated that exposure of MSCs to paclitaxel led to incorporation of the drug in MSCs. The paclitaxel-primed cells exhibited dose-dependent antiangiogenic and antitumor activity in vitro (Pessina et al., 2011). However, the use of MSCs as cytotoxic drug carriers has been limited by the overexpression of drug efflux transporters such as P-glycoprotein, resulting in poor drug-loading capacity (Dai et al., 2013; Sadhukha et al., 2014). Additionally, small molecules are subjected to rapid diffusional clearance out of the cells.

To overcome these drawbacks, a number of groups including ours have started investigating nanoparticle (NP)-encapsulated forms of drugs, which can increase the drug-carrying capacity of MSCs. NPs not only conceal drug molecules from the efflux transporters but also limit their diffusional clearance (Sadhukha et al., 2014; Zhang et al., 2015; Layek et al., 2016, 2018; Yao et al., 2017; Wang et al., 2018b; Moku et al., 2019). Table 2 summarizes the various studies that have reported engineering of MSCs with NPs for applications such as targeted tumor therapy, imaging, and cell tracking. Drug-loaded NPs can be incorporated in MSCs either via intracellular uptake

TABLE 2

Nanoengineered MSCs used for tumor-targeted drug delivery

Delivery System	Engineering Technique	Tumor Model	Administration Route	Effect	Reference
Paclitaxel-loaded PLGA NPs	Endocytosis	A549 lung adenocarcinoma and Lewis lung carcinoma	Intravenous injection	<ul style="list-style-type: none"> Improved biodistribution in lung tumors Improved antitumor efficacy Reduced dose dependent toxicity 	Layek et al., 2018
DOX-polymer conjugates	Receptor-dependent endocytosis	Intracerebral glioma	Intracranial administration	<ul style="list-style-type: none"> Enhanced penetration and sustained release of doxorubicin in tumor Improved survival 	Zhang et al., 2015
Biotinylated DOX-polymer conjugates	Endocytosis and membrane anchoring via avidin-biotin complex	Metastatic pulmonary breast cancer	Intravenous injection	<ul style="list-style-type: none"> Improved payload capacity Improved survival and tumor inhibition 	Yao et al., 2017
TAT-functionalized paclitaxel-loaded PLGA NPs	Cell penetrating peptide-mediated endocytosis	A549 lung adenocarcinoma	Intravenous injection	<ul style="list-style-type: none"> Improved payload capacity Improved survival and tumor inhibition 	Moku et al., 2019
Plasmonic-magnetic hybrid NPs (LDGI)	Endocytosis	TNBC	Intratumoral and intravenous injection	<ul style="list-style-type: none"> Enhanced migration and penetration Improved antitumor efficacy 	Xu et al., 2018
Antibody conjugated CNT/doxorubicin conjugate	Cell surface anchoring via antibody-antigen recognitions	A549 lung adenocarcinoma	Intravenous injection	<ul style="list-style-type: none"> Improved survival and tumor inhibition 	Kim et al., 2018
Antibody-conjugated doxorubicin-loaded silica nanorattles	Cell surface anchoring via antibody-antigen recognition	Glioma	Intratumoral administration	<ul style="list-style-type: none"> Improved penetration and tumor kill 	Li et al., 2011
Doxorubicin-loaded PLGA NPs	Simple endocytosis	Metastatic lung tumor	Intravenous injection	<ul style="list-style-type: none"> Enhanced targeting and permeation into tumor nest Significant reduction of lung metastases 	Zhao et al., 2017

CNT, carbon nanotube; DOX, doxorubicin; TAT, transactivator of transcription; TNBC, triple negative breast cancer.

or cell surface conjugation. Since MSCs home to the tumor site, NP-encapsulated drugs can be released locally at the tumor site over a prolonged duration and inhibit tumor growth. In this section, we describe the recent advances in nanoengineering of MSCs for tumor-targeted drug delivery.

Nanoengineering via cellular uptake. MSCs have been engineered with various types of NPs (organic and inorganic matrices) to enhance their drug-loading and therapeutic efficacy. Early studies used MSCs loaded with magnetic and fluorescently labeled NPs for use in diagnostic applications. Roger et al. (2010) demonstrated that coumarin-6 dye-loaded polylactide NPs and lipid nanocapsules were efficiently taken up by MSCs in a concentration- and time-dependent manner without affecting the viability and differentiation of MSCs. However, these studies did not investigate loading of chemotherapeutic agents in MSCs. The ability to load small molecule drugs is critical for clinical translation of MSCs (Krueger et al., 2018).

Achieving high payload capacity (the amount of drug that can be loaded per cell) is crucial to achieving therapeutic drug concentrations in the tumor tissue. On the other hand, loading a cytotoxic drug can adversely affect MSC viability and tumor tropism. Thus, loading of drugs containing NPs in MSCs needs to be carefully optimized to achieve effective tumor targeting. Factors that have been shown to be important in the intracellular uptake of NPs in other mammalian cells have a similar influence on the uptake of NPs in MSCs. It is widely established that NPs are taken up by endocytosis. It was first proposed by Panyam et al. (2002) that NPs formulated from certain polymers such as poly(L-lactide-co-glycolide) (PLGA) escape

the endosomal compartment, resulting in higher intracellular retention of the encapsulated drug. Another important attribute of NPs is protection of the encapsulated drug from efflux transporters present on the MSCs, which in turn results in higher uptake and greater payload capacity (Fig. 2). Several groups have demonstrated the presence of the efflux transporter P-glycoprotein on the surface of MSCs (Dai et al., 2013; Sadhukha et al., 2014). It has been demonstrated that uptake of NPs inside MSCs is concentration, size, and time dependent (Dai et al., 2013). The uptake is also influenced by the surface charge of NPs. The studies carried out by Dai et al. (2013) demonstrated that the migration of MSCs was compromised by loading of NPs, which could be attributed to the positive surface charge of chitosan NPs. In addition, the modification process required the use of MSCs at low passages, which may indicate the need for further optimization of this technology.

Sadhukha et al. (2014) reported an effective tumor-targeting strategy that relied on engineering MSCs with paclitaxel-loaded PLGA NPs (nanoengineered MSCs). In this study, MSCs demonstrated both concentration- and time-dependent uptake of NPs, with very little effect on cell viability. In addition, the nanoengineering process did not affect the migration or differentiation potential of MSCs in vitro and in vivo. Nanoengineered MSCs also exhibited a dose-dependent cytotoxicity against A549 human lung adenocarcinoma cells and MA148 human epithelial ovarian carcinoma cells in vitro. Most importantly, intravenous injection of nanoengineered MSCs resulted in selective tumor accumulation and retention in an orthotopic lung tumor model, while free

Fig. 2. Hypothetical mechanism of action of nanoengineered MSCs. Once nanoengineered MSCs home to tumors, while free drug is effluxed out of the MSCs by efflux transporters, nanoparticles can enter the cells by endocytosis, escape into the cytoplasm, and release the drug inside the cells. The free drug inside the cells can be effluxed out into the surrounding tumor cells to elicit antitumor response.

NPs were predominantly distributed in the liver and spleen. In a follow-up study, Layek et al. (2018) evaluated the efficacy of nanoengineered MSCs in the A549 orthotopic lung tumor model. Nanoengineered MSCs actively homed to the tumor sites and were capable of creating cellular drug depots that released the drug payload over an extended time period. Despite significantly lower total doses of paclitaxel used, nanoengineered MSCs led to more effective tumor growth inhibition and superior survival than solution or NP-encapsulated forms of paclitaxel. Pharmacokinetic and biodistribution studies have suggested improved antitumor efficacy of nanoengineered MSCs was primarily due to the higher drug exposure of paclitaxel in the tumor tissue. Furthermore, the common side effects of paclitaxel such as leukopenia were mitigated when the drug was delivered using nanoengineered MSCs, since the dose required to achieve improved anticancer efficacy was much lower compared with that of the paclitaxel solution and paclitaxel-loaded PLGA NPs. Taken together, these studies established the clinical potential of MSCs as delivery carriers for small molecule drugs.

In a similar study, Wang et al. (2018b) constructed nanoengineered MSCs with paclitaxel-loaded PLGA NPs. Nanoengineered MSCs showed enhanced and sustained release of paclitaxel compared with free paclitaxel-primed MSCs. Also, the nanoengineering process was found to have minimal effect on migration, cell cycle, and differentiation potential of MSCs. Additionally, nanoengineered MSCs demonstrated superior efficacy in an orthotopic rat glioma model following contralateral injection compared with that of free paclitaxel-primed MSCs or paclitaxel-loaded PLGA NPs.

Most of the nanoengineering strategies described previously rely on simple endocytosis to load drug-encapsulated NPs into MSCs. The rapid exocytosis of internalized NPs may result in insufficient drug loading and retention. To enhance drug loading in MSCs, Moku et al. (2019) evaluated PLGA NP surfaces functionalized with transactivator of transcription peptide. It was found that transactivator of transcription functionalization not only enhanced the intracellular drug accumulation of NPs but also increased their retention. Additionally, treatment with nanoengineered MSCs led to significantly ($P < 0.05$) higher tumor growth inhibition and improved survival in an orthotopic mouse model of lung cancer compared with those with free or NP-encapsulated paclitaxel.

In addition to tumor-targeted delivery nanoengineering MSCs have also been used as diagnostic aids for imaging tumors. For example, MSCs loaded with mesoporous silica nanoparticles coated with hyaluronic acid-based polymer and containing imaging agents (fluorescein isothiocyanate, Gd^{3+} , ^{64}Cu , and near-infrared dye ZW800) were used for optical, positron emission tomography, and magnetic resonance imaging (Huang et al., 2013). Another interesting example is a study conducted by Xu et al. (2018), in which MSCs loaded with plasmonic-magnetic hybrid NPs [lipids, doxorubicin, gold nanorods, and iron oxide nanoclusters (LDGI)] were fabricated for chemotherapy, photothermal therapy, and photoacoustic imaging of triple negative breast cancer tumors. LDGI hybrid NPs were efficiently taken up by the MSCs and the iron oxide nanoclusters of the LDGI upregulated CXCR4 expression, enhancing the migration of MSCs toward cancer cells. Light-irradiated disassembly of the LDGI NPs

facilitated the photothermal therapy and drug release. In vitro studies with MDA-MB 231 breast cancer cell lines demonstrated significant anticancer effect upon near-infrared laser irradiation. Intratumoral and intravenous administration of the MSC-LDGI in tumor models also showed improved migration and penetration to the tumor site, compared with LDGI alone. Therefore, this nanohybrid-loaded MSC delivery system could be developed as a synergistic approach combining chemotherapy, photothermal therapy, and photoacoustic imaging for effective cancer treatment.

Nanoengineering via surface anchoring. Despite several efforts to improve the therapeutic efficacy of nanoengineered MSCs, inadequate drug-loading capacity still restricts their use in small molecule drug delivery. To overcome the limited drug-loading capacity of MSCs, cell surface conjugation or dual drug-loading approaches comprising both endocytosis and membrane conjugation have been investigated. NPs can be attached to the surface of MSCs by covalent conjugation or physical association mediated by electrostatic and hydrophobic interactions. For instance, Yao et al. (2017) reported a novel nanoengineering strategy involving endocytosis of doxorubicin conjugates accompanied by cell surface anchoring of the drug conjugates via avidin-biotin complex formation. This strategy resulted in significantly higher drug loading than each of the individual modes. Such modified MSCs predominantly migrated to the lung where the foci of metastatic tumor were present. Importantly, these drug-carrying MSCs significantly inhibited tumor growth and prolonged the survival of tumor-bearing mice compared with free doxorubicin and doxorubicin conjugates.

In another study, Li et al. (2011) demonstrated the anchoring of doxorubicin-loaded silica nanorattles to MSCs using a cytomembrane antibody-antigen interaction. Silica nanorattles were conjugated to antibodies against antigens such as CD90 and CD73, which are expressed on bone marrow-derived MSCs (Crisan et al., 2008). Nanorattles were retained within the MSCs for at least 48 hours, which is a sufficient duration for tumor accumulation of the engineered MSCs. Furthermore, the engineered MSCs showed selective migration toward U251 glioma tumor cells and efficient doxorubicin delivery with greater and prolonged tumor distribution. It was concluded that this strategy has the potential to improve tumor targeting and reduce systemic toxicity.

Glycoengineering of MSCs to express synthetic functional groups such as azides is another exciting strategy that can be used to anchor drug-loaded NPs on MSC membrane. In metabolic glycoengineering, *N*-azidoacetylmannosamine-tetraacylated or another azide-containing sugar is metabolized by the cytidine-5'-monophospho-*N*-acetylneuraminic acid biosynthesis pathway of living cells into *N*-azidoacetylneuraminic acid, leading to the cell surface expression of azido-sialic acid containing *N*₃-linked glycoproteins (Du et al., 2009). Layek et al. (2016) demonstrated that culturing MSCs in *N*-azidoacetylmannosamine-tetraacylated supplemented media effectively generated azide-bearing sialic acid on the cell surface without affecting their viability, migration, and differentiation potential. Azide groups on the surface have been used to conjugate dibenzyl cyclooctyne (DBCO)-functionalized, paclitaxel-loaded NPs to MSCs, which allowed for significantly increased NP loading in MSCs (Layek et al., 2019). Incorporation of DBCO-functionalized NPs on MSCs did not affect the viability and migration of MSCs.

Such nanoengineered MSCs demonstrated greater tumor inhibition and improved survival than the free or NP-encapsulated paclitaxel in an orthotopic ovarian tumor mouse model.

Glycoengineered MSCs can also be used as tumor-localized anchors for a novel two-step tumor-targeting strategy. In a previous study, systemic administration of azide-expressing MSCs created a highly dense artificial receptor (azide groups) pool at tumor tissues, which then enhanced the tumor-targeting ability of DBCO-functionalized NPs via copper-free click chemistry (Fig. 3). This approach overcomes the lack of tumor specificity observed with conventional ligand-based techniques since these azide targets are not naturally expressed in the living system. Administration of azide-labeled MSCs followed by paclitaxel-loaded DBCO-functionalized NPs significantly inhibited tumor growth and enhanced survival compared with paclitaxel-loaded NPs in an orthotopic metastatic ovarian tumor model. Although the azide groups expressed on cell surfaces gradually diminish due to the intracellular hydrolysis of glycans by neuraminidase after internalization (Du et al., 2009; Yoon et al., 2017), their presence on the cell surface has been detected at least for 14 days (Lee et al., 2016). Thus, the azide groups can be used for repeated targeting of NPs to the tumor tissue.

Surface glycoengineering has been previously used to modify MSC homing properties to other tissues as well. Sackstein et al. (2008) employed glycoengineering approaches for converting native CD44 glycoform available on MSC surfaces to express hematopoietic cell E-selectin/L-selectin ligands. Glycoengineering did not affect the viability or potency of the MSCs and enhanced binding affinity to E-selectin, thereby increasing their migration ability to bone marrow. Similar strategies of cell surface glycoengineering were used safely and at reduced MSC payload to direct MSCs to ischemia-reperfusion sites in the porcine heart for improved clinical efficacy and successful regenerative therapy (Lo et al., 2016).

An important consideration in using MSCs for drug delivery is the potential protumorigenic effects of MSCs when they come in contact with tumor cells (Cuiffo and Karnoub, 2012; Rodini et al., 2018; Zong et al., 2018). To address this issue, nanoengineered systems that can kill the MSCs following their tumor accumulation are being evaluated. Kim et al. (2018) demonstrated the concept of codestruction of lung tumor cells by MSCs loaded with nanodrug conjugates. The authors reported that bone marrow-derived MSCs showed specific targeting toward lung tumors compared with others such as breast and brain tumors, and this was attributed to the affinity of MSCs toward CXCL12 and IL-8 secreted by lung cancer cells. MSCs were nanoengineered by conjugation with carbon nanotube doxorubicin either through surface engineering by CD73 and CD90 or through intracellular uptake. Surface-engineered MSCs showed 9-fold higher drug uptake and better tumor homing ability relative to that observed for MSCs in which nanotubes were incorporated through intracellular uptake. Surface-engineered MSCs demonstrated higher and prolonged cytotoxicity in H1975 lung cancer cells in vitro and significant reduction in tumor growth in A549 lung tumors in vivo. It was shown that potential destruction of surface-engineered MSCs by secreted chemokines from the dead tumor cells resulted in a bystander effect and improved tumor growth inhibition at a 100-fold lower dose when compared with that of conventional chemotherapeutic approaches.

Fig. 3. In vivo tumor tropism of glycoengineered MSCs (orthotopic ovarian tumor). (A) MA148-Luc ovarian tumor-bearing animals were injected with MSC/cyanine5.5 (Cy5.5) intraperitoneally and imaged at different time points. Tumor-free animals injected intraperitoneally with MSC-Cy5.5 were used as control. Representative bioluminescence images (at 1 day) for tumor-free (i) and tumor-bearing (viii) animals and representative fluorescence images at different time intervals for control (ii–vii) and tumor-bearing (ix–xvi) animals are shown. (B) Tissue distribution of glycoengineered MSCs at the end of the study. The animals were euthanized at 4 weeks and the organs were collected and imaged. Bioluminescence and fluorescence images respectively of kidneys (i and x), brain (ii and xi), liver (iii and xii), abdominal wall (iv and xiii), spleen (v and xiv), lungs (vi and xv), heart (vii and xvi), ovarian tumor (viii and xvii), and abdominal tumor (ix and xviii) are shown. (C) Quantitative fluorescence intensity from the different organs at the end of the study (10 days for control and 28 days for tumor-bearing animals). Data represent mean $\pm$ S.D.; $n = 3$ for treated and $n = 2$ for control; * $P < 0.05$ compared with control ovary. Reproduced with permission from Layek et al. (2016).

Challenges and Future Directions (Regulatory Considerations for the Clinical Translation of MSC-Based Cancer Therapies)

A key concern with the use of MSCs for drug delivery is their potential to promote tumor growth. Most studies evaluating the use of MSCs for the delivery of anticancer agents have demonstrated tumor-suppressive effects. However, other studies suggest that MSCs (in the absence of anticancer agents) can promote tumor growth when coinjected with cancer cells or under hypoxic conditions. Extracellular vesicles released from MSCs have been shown to contain tumor-supportive proteins such as platelet-derived growth factor receptor- β , tissue inhibitor of metalloproteinase-1, etc. (Djouad et al., 2003, 2006; Zhu et al., 2006; Karnoub et al., 2007; Muehlberg et al., 2009; Vallabhaneni et al., 2015; Lee and Hong, 2017). MSCs were shown to support the growth of

tumor vasculature by either secreting proangiogenic factors such as vascular endothelial growth factor (Kinnaird et al., 2004; Potapova et al., 2007) or differentiation into pericytes, which further promote the growth of vasculature (Al-Khaldi et al., 2003). Hwang et al. (2008) found that MSCs promote the recruitment of tumor fibroblasts, which are known to promote tumor growth. In addition, MSCs are considered to possess immunosuppressive properties and promote tumor metastasis (Krampera et al., 2003; Karnoub et al., 2007). Interestingly, MSCs were shown to inhibit tumor capillary growth by intercalating between endothelial cells, establishing gap junctional communications and increased generation of reactive oxygen species (Otsu et al., 2009). Otsu et al. (2009) concluded that nonfunctionalized MSCs can be cytotoxic to tumor cells at high numbers. These contradictory observations may indicate the context-dependent effects of MSCs. Therefore, it is crucial that the underlying mechanisms behind

TABLE 3
Marketed MSC-based products

Product	Type of MSCs	Indication	Company	Country of Approval	Year of Approval
Queencell	Autologous adipose derived	Connective tissue disorder	Anterogen Ltd.	South Korea	2010
Cartistem	Allogeneic umbilical cord blood	Traumatic and degenerative osteoarthritis	Medipost Ltd.	South Korea	2011
Cellgram-AMI (Hearticellgram-AMI)	Autologous bone marrow derived	Acute myocardial infarction	FCB-Pharmicell Ltd.	South Korea	2011
Cupistem	Autologous adipose derived	Crohn's fistula	Anterogen Ltd.	South Korea	2012
Neuronata-r	Autologous bone marrow	ALS	Corestem Inc.	South Korea	2014
TEMCELL HS	Allogeneic	Acute radiation injury	JCR Pharmaceuticals Ltd., Licensee of Mesoblast Ltd.	Japan	2016
Stempeucel	Allogeneic stromal	Critical limb ischemia	Stempeutics Research Pvt. Ltd.	India	2016
Alofisel (Darvadstrocel)	Allogeneic adipose tissue	Complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohn's disease	Takeda Pharmaceutical Company Ltd.	Europe	2018

ALS, amyotrophic lateral sclerosis.

these observations are further delineated to enable effective clinical translation of MSC-based therapies for targeting cancer.

Another potential limitation is that MSCs harvested from different tissues such as bone marrow or adipose share some similar features including morphology and cell surface markers, but may exhibit differences in other biologic properties such as differentiation capabilities (Xu et al., 2017). Altered in vivo phenotype could result in variations in the effectiveness of administered therapies. Thus, it is essential to establish standardized procedures and perform stringent quality control to ensure consistency of MSCs being used (Le Blanc and Davies, 2018).

The number of investigational new drug/biologics license application submissions to the Food and Drug Administration and registered clinical trials of MSC-based products has increased exponentially in the past decade (Olsen et al., 2018). According to the National Institutes of Health database, there are 703 MSC-based clinical trials in different disease areas as of May 1, 2019, with known status (<https://clinicaltrials.gov/>). Several MSC-based products have been approved globally, as shown in Table 3. Despite considerable interest in utilizing MSCs for varied therapeutic purposes, several regulatory hurdles limit the effective clinical translation of MSC-based cell therapies. One of the major hurdles for clinical application of MSCs is the lack of clear understanding of their in vivo fate and dose-response relationship in humans. There is a clear need to develop effective analytical methods to track MSCs in the body in order to establish their pharmacokinetic and pharmacodynamic profiles. The fact that MSCs can be isolated and expanded from a plethora of tissues in the body and that MSCs from different sources have slightly varied biologic effects potentially increase the regulatory burden. Diversity in the source of MSCs also occurs in allogeneic donors, and there is a trend to move toward autologous sources of MSCs. However, this could increase the cost of MSC-based therapy. MSCs derived from bone marrow of patients with leukemia or multiple myeloma may be contaminated with clonogenic tumor cells and could lead to relapse in these patients (Champlin, 2003).

Additionally, standardized good manufacturing practices need to be established for the production of MSCs. Various cell

culture factors such as FBS concentration, oxygen content, and additional growth factor supplements vary widely, leading to significant variability in the properties of manufactured MSCs (Mendicino et al., 2014). As previously discussed, there is a lack of clear understanding of the molecular mechanisms and pathways associated with the tumor-suppressive or tumor-promoting role of MSCs. The Food and Drug Administration has issued various guidelines for cell and gene therapies to ensure that the products conform to the desired standards and are safe and effective for use (Food and Drug Administration (FDA), 1998, 2011). Also, the International Society for Stem Cell Research has published guidelines for the clinical translation of stem cells for promoting medication innovation, protecting patients, preserving rigor, and ensuring integrity in stem cell-based therapies (Hyun et al., 2008).

Concluding Remarks

MSCs have emerged as excellent candidates for cell-based therapy in the fields of tissue engineering, regenerative medicine, and targeted delivery of therapeutics owing to their multipotency, self-renewal, and homing abilities. To further advance MSC-based therapies, novel approaches are being explored for engineering MSCs with genes, proteins, and chemotherapeutics. Nanoengineering MSCs with drug-loaded NPs by either surface conjugation or through internalization can increase the drug payload that can be delivered to the tumor tissue. Identifying the molecular mechanisms that contribute to the tumor tropism along with tuning the engineering conditions can further improve their effectiveness as drug delivery vehicles.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Cheng, Nethi, Rath, Layek, Prabha.

References

- Ab Kadir R, Zainal Ariffin SH, Megat Abdul Wahab R, Kermani S, and Senafi S (2012) Characterization of mononucleated human peripheral blood cells. *ScientificWorldJournal* 2012:843843.
- Afanasyev BV, Elstner EE, and Zander AR (2009) A. J. Friedenstein, founder of the mesenchymal stem cell concept. *Cell Ther Transplant* 1:35–38.
- Ahmed AU and Lesniak MS (2011) Glioblastoma multiforme: can neural stem cells deliver the therapeutic payload and fulfill the clinical promise? *Expert Rev Neurother* 11:775–777.

- Al-Khaldi A, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K, and Galipeau J (2003) Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neo-angiogenic response in vivo. *Gene Ther* **10**:621–629.
- Amara I, Touati W, Beaune P, and de Waziers I (2014) Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors. *Biochimie* **105**:4–11.
- Ansboro S, Roelofs AJ, and De Bari C (2017) Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both? *Curr Opin Rheumatol* **29**:201–207.
- Baghaei K, Hashemi SM, Tokhanbigli S, Asadi Rad A, Assadzadeh-Aghdaei H, Sharifian A, and Zali MR (2017) Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow. *Gastroenterol Hepatol Bed Bench* **10**:208–213.
- Ball SG, Shuttleworth CA, and Kielty CM (2007) Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. *J Cell Biol* **177**: 489–500.
- Bartsch G, Yoo JJ, De Coppi P, Siddiqui MM, Schuch G, Pohl HG, Fuhr J, Perin L, Soker S, and Atala A (2005) Propagation, expansion, and multilineage differentiation of human somatic stem cells from dermal progenitors. *Stem Cells Dev* **14**: 337–348.
- Batrakova EV, Li S, Reynolds AD, Mosley RL, Bronich TK, Kabanov AV, and Gendelman HE (2007) A macrophage-nanozyme delivery system for Parkinson's disease. *Bioconjug Chem* **18**:1498–1506.
- Bazak R, Hourri M, El Achy S, Kamel S, and Refaat T (2015) Cancer active targeting by nanoparticles: a comprehensive review of literature. *J Cancer Res Clin Oncol* **141**:769–784.
- Bexell D, Gunnarsson S, Svensson A, Tormin A, Henriques-Oliveira C, Siesjö P, Paul G, Salford LG, Scheding S, and Bengzon J (2012) Rat multipotent mesenchymal stromal cells lack long-distance tropism to 3 different rat glioma models. *Neurosurgery* **70**:731–739.
- Bokhoven M, Stephen SL, Knight S, Gevers EF, Robinson IC, Takeuchi Y, and Collins MK (2009) Insertional gene activation by lentiviral and gammaretroviral vectors. *J Virol* **83**:283–294.
- Bruder SP, Jaiswal N, and Haynesworth SE (1997) Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. *J Cell Biochem* **64**:278–294.
- Bruder SP, Kurth AA, Shea M, Hayes WC, Jaiswal N, and Kadiyala S (1998) Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. *J Orthop Res* **16**:155–162.
- Brynskikh AM, Zhao Y, Mosley RL, Li S, Boska MD, Klyachko NL, Kabanov AV, Gendelman HE, and Batrakova EV (2010) Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. *Nanomedicine (Lond)* **5**:379–396.
- Food and Drug Administration (FDA) (1998) Guidance for Industry: Guidance for human somatic cell therapy and gene therapy. US. Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-human-somatic-cell-therapy-and-gene-therapy>.
- Food and Drug Administration (FDA) (2011) Guidance for Industry: Potency tests for cellular and gene therapy products. US. Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-tests-cellular-and-gene-therapy-products>.
- Chamberlain G, Fox J, Ashton B, and Middleton J (2007) Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells* **25**:2739–2749.
- Chambers E and Mitragotri S (2007) Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. *Exp Biol Med (Maywood)* **232**:958–966.
- Champlin R (2003) *Selection of Autologous or Allogeneic Transplantation*. Holland-Frei Cancer Medicine, 6th ed, BC Decker, Hamilton, ON, Canada.
- Chen X, Lin X, Zhao J, Shi W, Zhang H, Wang Y, Kan B, Du L, Wang B, Wei Y, et al. (2008) A tumor-selective bioreporter with prolonged impact on established metastases based on cytokine gene-engineered MSCs. *Mol Ther* **16**:749–756.
- Cheng H, Kastrop CJ, Ramanathan R, Siegwart DJ, Ma M, Bogatyrev SR, Xu Q, Whitehead KA, Langer R, and Anderson DG (2010) Nanoparticulate cellular patches for cell-mediated tumorotropic delivery. *ACS Nano* **4**:625–631.
- Cheng Y, Li L, Wang D, Guo Q, He Y, Liang T, Sun L, Wang X, Cheng Y, and Zhang G (2017) Characteristics of human endometrium-derived mesenchymal stem cells and their tropism to endometriosis. *Stem Cells Int* **2017**:4794827.
- Cheng Y, Morshed R, Cheng SH, Tobias A, Auffinger B, Wainwright DA, Zhang L, Yunis C, Han Y, Chen CT, et al. (2013) Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. *Small* **9**:4123–4129.
- Choi MR, Bardhan R, Stanton-Maxey KJ, Badve S, Nakshatri H, Stantz KM, Cao N, Halas NJ, and Clare SE (2012) Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. *Cancer Nanotechnol* **3**:47–54.
- Choi MR, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, Akin D, Badve S, Sturgis J, Robinson JP, Bashir R, et al. (2007) A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. *Nano Lett* **7**:3759–3765.
- Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, et al. (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* **3**:301–313.
- Cuiffo BG and Karnoub AE (2012) Mesenchymal stem cells in tumor development: emerging roles and concepts. *Cell Adhes Migr* **6**:220–230.
- Dai T, Yang E, Sun Y, Zhang L, Zhang L, Shen N, Li S, Liu L, Xie Y, Wu S, et al. (2013) Preparation and drug release mechanism of CTS-TAX-NP-MSCs drug delivery system. *Int J Pharm* **456**:186–194.
- De Becker A and Riet IV (2016) Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? *World J Stem Cells* **8**:73–87.
- Dennis JE, Merriam A, Awadallah A, Yoo JU, Johnstone B, and Caplan AI (1999) A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse. *J Bone Miner Res* **14**:700–709.
- Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, and Noël D (2006) Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. *Transplantation* **82**:1060–1066.
- Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noël D, and Jorgensen C (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. *Blood* **102**:3837–3844.
- Droujinine IA, Eckert MA, and Zhao W (2013) To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells. *Oncotarget* **4**:651–664.
- Du J, Meledeo MA, Wang Z, Khanna HS, Paruchuri VD, and Yarema KJ (2009) Metabolic glycoengineering: sialic acid and beyond. *Glycobiology* **19**:1382–1401.
- Fitzsimmons REB, Mazurek MS, Soos A, and Simmons CA (2018) Mesenchymal stromal/stem cells in regenerative medicine and tissue engineering. *Stem Cells Int* **2018**:8031718.
- Friedenstein AJ, Piatetzky-Shapiro II, and Petrakova KV (1966) Osteogenesis in transplants of bone marrow cells. *J Embryol Exp Morphol* **16**:381–390.
- Gao H, Koneru R, Glod J, and Banerjee D (2007) The JAK2/STAT3-mediated SDF-1/CXCR4 axis promotes mesenchymal stem cell migration in response to the tumor microenvironment. *Cancer Res* **67**:573.
- García-Castro J, Trigueros C, Madrenas J, Pérez-Simón JA, Rodríguez R, and Menéndez P (2008) Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. *J Cell Mol Med* **12**:2552–2565.
- Gronthos S, Brahmi J, Li W, Fisher LW, Cherman N, Boyde A, DenBesten P, Robey PG, and Shi S (2002) Stem cell properties of human dental pulp stem cells. *J Dent Res* **81**:531–535.
- Hernanda PY, Pedroza-Gonzalez A, Sprengers D, Peppelenbosch MP, and Pan Q (2014) Multipotent mesenchymal stromal cells in liver cancer: implications for tumor biology and therapy. *Biochim Biophys Acta* **1846**:439–445.
- Hodgkinson CP, Gomez JA, Mirosou M, and Dzau VJ (2010) Genetic engineering of mesenchymal stem cells and its application in human disease therapy. *Hum Gene Ther* **21**:1513–1526.
- Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, and Sarkar S (2014) Drug resistance in cancer: an overview. *Cancers (Basel)* **6**:1769–1792.
- Huang B, Abraham WD, Zheng Y, Bustamante López SC, Luo SS, and Irvine DJ (2015) Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. *Sci Transl Med* **7**:291ra94.
- Huang X, Zhang F, Wang H, Niu G, Choi KY, Swierczewska M, Zhang G, Gao H, Wang Z, Zhu L, et al. (2013) Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery. *Biomaterials* **34**:1772–1780.
- Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, and Logsdon CD (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. *Cancer Res* **68**:918–926.
- Hyun I, Lindvall O, Ahrlund-Richter L, Cattaneo E, Cavazzana-Calvo M, Cossu G, De Luca M, Fox IJ, Gerstle C, Goldstein RA, et al. (2008) New ISSCR guidelines underscore major principles for responsible translational stem cell research. *Cell Stem Cell* **3**:607–609.
- Kadiyala S, Young RG, Thiede MA, and Bruder SP (1997) Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro. *Cell Transplant* **6**:125–134.
- Kang SG, Shinjima N, Hossain A, Gumin J, Yong RL, Colman H, Marini F, Andreeff M, and Lang FF (2010) Isolation and perivascular localization of mesenchymal stem cells from mouse brain. *Neurosurgery* **67**:711–720.
- Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, and Weinberg RA (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. *Nature* **449**:557–563.
- Kim HJ and Park JS (2017) Usage of human mesenchymal stem cells in cell-based therapy: advantages and disadvantages. *Dev Reprod* **21**:1–10.
- Kim SW, Lee YK, Hong JH, Park JY, Choi YA, Lee DU, Choi J, Sym SJ, Kim SH, and Khang D (2018) Mutual destruction of deep lung tumor tissues by nanodrug-conjugated stealth mesenchymal stem cells. *Adv Sci (Weinh)* **5**:1700860.
- Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, and Epstein SE (2004) Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circ Res* **94**:678–685.
- Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, and Dazzi F (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. *Blood* **101**:3722–3729.
- Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, and Brennen WN (2018) Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise. *Stem Cells Transl Med* **7**:651–663.
- Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, Altanerova V, and Altaner C (2008) Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. *J Gene Med* **10**:1071–1082.
- Laverdet B, Micallef L, Lebreton C, Mollard J, Lataillade JJ, Coulomb B, and Desmoulière A (2014) Use of mesenchymal stem cells for cutaneous repair and skin substitute elaboration. *Pathol Biol (Paris)* **62**:108–117.
- Layek B, Sadhukha T, Panyam J, and Prabha S (2018) Nano-engineered mesenchymal stem cells increase therapeutic efficacy of anticancer drug through true active tumor targeting. *Mol Cancer Ther* **17**:1196–1206.
- Layek B, Sadhukha T, and Prabha S (2016) Glycoengineered mesenchymal stem cells as an enabling platform for two-step targeting of solid tumors. *Biomaterials* **88**:97–109.
- Layek B, Sehgal D, Argenta PA, Panyam J, and Prabha S (2019) Nanoengineering of mesenchymal stem cells via surface modification for efficient cancer therapy. *Adv. Therap*. DOI: 10.1002/adtp.201900043.

- Le Blanc K and Davies LC (2018) MSCs—cells with many sides. *Cytotherapy* **20**:273–278.
- Lee HY and Hong IS (2017) Double-edged sword of mesenchymal stem cells: cancer-promoting versus therapeutic potential. *Cancer Sci* **108**:1939–1946.
- Lee M, Jeong SY, Ha J, Kim M, Jin HJ, Kwon SJ, Chang JW, Choi SJ, Oh W, Yang YS, et al. (2014) Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. *Biochem Biophys Res Commun* **446**:983–989.
- Lee SY, Lee S, Lee J, Yhee JY, Yoon HI, Park SJ, Koo H, Moon SH, Lee H, Cho YW, et al. (2016) Non-invasive stem cell tracking in hindlimb ischemia animal model using bio-orthogonal copper-free click chemistry. *Biochem Biophys Res Commun* **479**:779–786.
- Li L, Guan Y, Liu H, Hao N, Liu T, Meng X, Fu C, Li Y, Qu Q, Zhang Y, et al. (2011) Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. *ACS Nano* **5**:7462–7470.
- Lin W, Xu L, Zwingerberger S, Gibon E, Goodman SB, and Li G (2017) Mesenchymal stem cells homing to improve bone healing. *J Orthop Translat* **9**:19–27.
- Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, Clise-Dwyer K, Wang RY, Zhang W, Yuan X, et al. (2010) Mesenchymal stem cells overexpressing IFN- β inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. *Cancer Microenviron* **3**:83–95.
- Liu L, Chen JX, Zhang XW, Sun Q, Yang L, Liu A, Hu S, Guo F, Liu S, Huang Y, et al. (2018) Chemokine receptor 7 overexpression promotes mesenchymal stem cell migration and proliferation via secreting Chemokine ligand 12. *Sci Rep* **8**:204.
- Lo CY, Weil BR, Palka BA, Momeni A, Canty JM Jr, and Neelamegham S (2016) Cell surface glycoengineering improves selectin-mediated adhesion of mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs): pilot validation in porcine ischemia-reperfusion model. *Biomaterials* **74**:19–30.
- Mahla RS (2016) Stem cells applications in regenerative medicine and disease therapeutics. *Int J Cell Biol* **2016**:6940283.
- Mendicino M, Bailey AM, Wonnacott K, Puri RK, and Bauer SR (2014) MSC-based product characterization for clinical trials: an FDA perspective. *Cell Stem Cell* **14**:141–145.
- Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, Schambach A, Charrier S, Galy A, Thrasher AJ, et al. (2009) Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. *Mol Ther* **17**:1919–1928.
- Moku G, Layek B, Trautman L, Putnam S, Panyam J, and Prabha S (2019) Improving payload capacity and anti-tumor efficacy of mesenchymal stem cells using TAT peptide functionalized polymeric nanoparticles. *Cancers (Basel)* **11**:491.
- Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, Ferrone S, Barnaba V, and Pistoia V (2008) Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. *Stem Cells* **26**:1275–1287.
- Morigi M, Rota C, and Remuzzi G (2016) Mesenchymal stem cells in kidney repair. *Methods Mol Biol* **1416**:89–107.
- Muehlberg FL, Song YH, Krohn A, Pinilla SP, Droll LH, Leng X, Seidensticker M, Ricke J, Altman AM, Devarajan E, et al. (2009) Tissue-resident stem cells promote breast cancer growth and metastasis. *Carcinogenesis* **30**:589–597.
- Mueller LP, Luetzkendorf J, Widder M, Nerger K, Caysa H, and Mueller T (2011) TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. *Cancer Gene Ther* **18**:229–239.
- Müller FJ, Snyder EY, and Loring JF (2006) Gene therapy: can neural stem cells deliver? *Nat Rev Neurosci* **7**:75–84.
- Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, et al. (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. *Cancer Res* **65**:3307–3318.
- Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, and Hamada H (2004) Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. *Gene Ther* **11**:1155–1164.
- Noriega DC, Ardura F, Hernández-Ramajo R, Martín-Ferrero MA, Sánchez-Lite I, Toribio B, Alberca M, García V, Moraleda JM, Sánchez A, et al. (2017) Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: a randomized controlled trial. *Transplantation* **101**:1945–1951.
- Olsen TR, Ng KS, Lock LT, Ahsan T, and Rowley JA (2018) Peak MSC—are we there yet? *Front Med (Lausanne)* **5**:178.
- Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S, and Bhattacharya J (2009) Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. *Blood* **113**:4197–4205.
- Panyam J, Zhou WZ, Prabha S, Sahoo SK, and Labhasetwar V (2002) Rapid endolysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. *FASEB J* **16**:1217–1226.
- Park JS, Suryaprakash S, Lao YH, and Leong KW (2015) Engineering mesenchymal stem cells for regenerative medicine and drug delivery. *Methods* **84**:3–16.
- Pendleton C, Li Q, Chesler DA, Yuan K, Guerrero-Cazares H, and Quinones-Hinojosa A (2013) Mesenchymal stem cells derived from adipose tissue vs bone marrow: in vitro comparison of their tropism towards gliomas. *PLoS One* **8**:e58198.
- Pessina A, Bonomi A, Cocci V, Ivernieri G, Navone S, Cavicchini L, Sisto F, Ferrari M, Viganò L, Locatelli A, et al. (2011) Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. *PLoS One* **6**:e28321.
- Ponte AL, Marais E, Gallay N, Langonné A, Delorme B, Héralaut O, Charbord P, and Domenech J (2007) The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. *Stem Cells* **25**:1737–1745.
- Potapova IA, Gaudette GR, Brink PR, Robinson RB, Rosen MR, Cohen IS, and Doronin SV (2007) Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. *Stem Cells* **25**:1761–1768.
- Relation T, Yi T, Guess AJ, La Perle K, Otsuru S, Hasgur S, Dominici M, Breuer C, and Horwitz EM (2018) Intratumoral delivery of interferon- γ -secreting mesenchymal stromal cells repolarizes tumor-associated macrophages and suppresses neuroblastoma proliferation in vivo. *Stem Cells* **36**:915–924.
- Riekstina U, Muceniece R, Cakstina I, Muiznieks I, and Ancans J (2008) Characterization of human skin-derived mesenchymal stem cell proliferation rate in different growth conditions. *Cytotechnology* **58**:153–162.
- Rodini CO, Gonçalves da Silva PB, Assoni AF, Carvalho VM, and Okamoto OK (2018) Mesenchymal stem cells enhance tumorigenic properties of human glioblastoma through independent cell-cell communication mechanisms. *Oncotarget* **9**:24766–24777.
- Roger M, Clavreul A, Venier-Julienne MC, Passirani C, Sindji L, Schiller P, Montero-Menei C, and Menei P (2010) Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. *Biomaterials* **31**:8393–8401.
- Rosenblum D, Joshi N, Tao W, Karp JM, and Peer D (2018) Progress and challenges towards targeted delivery of cancer therapeutics. *Nat Commun* **9**:1410.
- Ryu CH, Park SH, Park SA, Kim SM, Lim JY, Jeong CH, Yoon WS, Oh WI, Sung YC, and Jeun SS (2011) Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. *Hum Gene Ther* **22**:733–743.
- Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, and Wohlgemuth R (2008) Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. *Nat Med* **14**:181–187.
- Sadhukha T, O'Brien TD, and Prabha S (2014) Nano-engineered mesenchymal stem cells as targeted therapeutic carriers. *J Control Release* **196**:243–251.
- Schmidt A, Ladage D, Schinköthe T, Klausmann U, Ulrichs C, Klinz FJ, Brixius K, Arnold S, Desai B, Mehlhorn U, et al. (2006) Basic fibroblast growth factor controls migration in human mesenchymal stem cells. *Stem Cells* **24**:1750–1758.
- Schnarr K, Mooney R, Weng Y, Zhao D, Garcia E, Armstrong B, Annala AJ, Kim SU, Aboudy KS, and Berlin JM (2013) Gold nanoparticle-loaded neural stem cells for photothermal ablation of cancer. *Adv Healthc Mater* **2**:976–982.
- Solchaga LA, Penick KJ, and Welter JF (2011) Chondrogenic differentiation of bone marrow-derived mesenchymal stem cells: tips and tricks. *Methods Mol Biol* **698**:253–278.
- Song C, Xiang J, Tang J, Hirst DG, Zhou J, Chan KM, and Li G (2011) Thymidine kinase gene modified bone marrow mesenchymal stem cells as vehicles for antitumor therapy. *Hum Gene Ther* **22**:439–449.
- Squillaro T, Peluso G, and Galderisi U (2016) Clinical trials with mesenchymal stem cells: an update. *Cell Transplant* **25**:829–848.
- Stewart K, Walsh S, Screen J, Jefferiss CM, Chainey J, Jordan GR, and Beresford JN (1999) Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. *J Bone Miner Res* **14**:1345–1356.
- Sun Z, Wang S, and Zhao RC (2014) The roles of mesenchymal stem cells in tumor inflammatory microenvironment. *J Hematol Oncol* **7**:14–14.
- Takeuchi M, Takeuchi K, Kohara A, Satoh M, Shioda S, Ozawa Y, Ohtani A, Morita K, Hirano T, Terai M, et al. (2007) Chromosomal instability in human mesenchymal stem cells immortalized with human papilloma virus E6, E7, and hTERT genes. *In Vitro Cell Dev Biol Anim* **43**:129–138.
- Tang C, Russell PJ, Martiniello-Wilks R, Rasko JEJ, and Khatri A (2010) Concise review: nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy? *Stem Cells* **28**:1686–1702.
- Thakker R and Yang P (2014) Mesenchymal stem cell therapy for cardiac repair. *Curr Treat Options Cardiovasc Med* **16**:323.
- Touboul C, Lis R, Al Farsi H, Raynaud CM, Warfa M, Althawadi H, Mery E, Mirshahi M, and Rafii A (2013) Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniotic membrane based 3D model. *J Transl Med* **11**:28.
- Vallabhaneni KC, Penformis P, Dhule S, Guilloneau F, Adams KV, Mo YY, Xu R, Liu Y, Watabe K, Vemuri MC, et al. (2015) Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites. *Oncotarget* **6**:4953–4967.
- van Vliet P, Sluijter JP, Doevendans PA, and Goumans MJ (2007) Isolation and expansion of resident cardiac progenitor cells. *Expert Rev Cardiovasc Ther* **5**:33–43.
- Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W, et al. (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Exp Hematol* **33**:1402–1416.
- Wang M, Yuan Q, and Xie L (2018a) Mesenchymal stem cell-based immunomodulation: properties and clinical application. *Stem Cells Int* **2018**:3057624.
- Wang X, Gao J, Ouyang X, Wang J, Sun X, and Lv Y (2018b) Mesenchymal stem cells loaded with paclitaxel-poly(lactide-co-glycolic acid) nanoparticles for glioma-targeting therapy. *Int J Nanomedicine* **13**:5231–5248.
- Xu C, Feng Q, Wang H, Wang G, Huang L, Bai Q, Zhang C, Wang Y, Chen Y, Cheng Q, et al. (2018) A light-triggered mesenchymal stem cell delivery system for photoacoustic imaging and chemo-photothermal therapy of triple negative breast cancer. *Adv Sci (Weinh)* **5**:1800382.
- Xu G, Jiang XD, Xu Y, Zhang J, Huang FH, Chen ZZ, Zhou DX, Shang JH, Zou YX, Cai YQ, et al. (2009) Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. *Cell Biol Int* **33**:466–474.
- Xu L, Liu Y, Sun Y, Wang B, Xiong Y, Lin W, Wei Q, Wang H, He W, Wang B, et al. (2017) Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. *Stem Cell Res Ther* **8**:275.
- Yang D, Sun S, Wang Z, Zhu P, Yang Z, and Zhang B (2013) Stromal cell-derived factor-1 receptor CXCR4-overexpressing bone marrow mesenchymal stem cells accelerate wound healing by migrating into skin injury areas. *Cell Reprogram* **15**:206–215.
- Yang X, Du J, Xu X, Xu C, and Song W (2014) IFN- γ -secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway. *J Immunol Res* **2014**:318098.

- Yao S, Li X, Liu J, Sun Y, Wang Z, and Jiang Y (2017) Maximized nanodrug-loaded mesenchymal stem cells by a dual drug-loaded mode for the systemic treatment of metastatic lung cancer. *Drug Deliv* **24**:1372–1383.
- Yin J, Kim JK, Moon JH, Beck S, Piao D, Jin X, Kim SH, Lim YC, Nam DH, You S, et al. (2011) hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. *Mol Ther* **19**:1161–1169.
- Yoon HY, Koo H, Kim K, and Kwon IC (2017) Molecular imaging based on metabolic glycoengineering and bioorthogonal click chemistry. *Biomaterials* **132**:28–36.
- Zhang X, Hirai M, Cantero S, Ciubotariu R, Dobrila L, Hirsh A, Igura K, Satoh H, Yokomi I, Nishimura T, et al. (2011) Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue. *J Cell Biochem* **112**:1206–1218.
- Zhang X, Yao S, Liu C, and Jiang Y (2015) Tumor tropic delivery of doxorubicin-polymer conjugates using mesenchymal stem cells for glioma therapy. *Biomaterials* **39**:269–281.
- Zhao K and Liu Q (2016) The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. *J Hematol Oncol* **9**:46.
- Zhao Y, Haney MJ, Klyachko NL, Li S, Booth SL, Higginbotham SM, Jones J, Zimmerman MC, Mosley RL, Kabanov AV, et al. (2011) Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles. *Nanomedicine (Lond)* **6**:25–42.
- Zhao Y, Tang S, Guo J, Alahdal M, Cao S, Yang Z, Zhang F, Shen Y, Sun M, Mo R, et al. (2017) Targeted delivery of doxorubicin by nano-loaded mesenchymal stem cells for lung melanoma metastases therapy. *Sci Rep* **7**:44758.
- Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, Cao W, Han C, and Chen Y (2006) Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. *Exp Mol Pathol* **80**:267–274.
- Zong C, Zhang H, Yang X, Gao L, Hou J, Ye F, Jiang J, Yang Y, Li R, Han Z, et al. (2018) The distinct roles of mesenchymal stem cells in the initial and progressive stage of hepatocarcinoma. *Cell Death Dis* **9**:345.

Address correspondence to: Dr. Swayam Prabha, Department of Experimental and Clinical Pharmacology, University of Minnesota, 308 Harvard Street South East, 9-127D WDH, Minneapolis, MN 55455. E-mail: prabh025@umn.edu